Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders-Reference-Cited by-同舟云学术

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

Published:2018-10-30 Issue:1 Volume:266 Page:57-67
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Ellrichmann Gisa^ORCID,Bolz Jan,Peschke Maren,Duscha Alexander,Hellwig Kerstin,Lee De-Hyung,Linker Ralf A.,Gold Ralf,Haghikia Aiden

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/article/10.1007/s00415-018-9092-4/fulltext.html

Reference19 articles.

1. Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K (2017) Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm 4:e360

2. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395–400

3. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67:452–461

4. Casan JML, Wong J, Northcott MJ, Opat S (2018) Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccine Immunother 10:1–22

5. Haghikia A, Dendrou CA, Schneider R, Gruter T, Postert T, Matzke M, Stephanik H, Fugger L, Gold R (2017) Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol 16:104–106

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Memory B cell–guided extended interval dosing of ocrelizumab in multiple sclerosis;Multiple Sclerosis Journal;2024-05-20

2. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-05

3. Rituximab in non-systemic vasculitic neuropathy: a single-center experience;Journal of Neurology;2024-04-24

4. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability;Drugs;2024-03

5. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder;Scientific Reports;2024-02-12